Neok Biotech’s $75 million series A venture round, which took the California-based biotech out of stealth mode, was not the ...

French pharma major Sanofi today revealed it has agreed to acquire Dynavax Technologies, a US vaccines company with a ...

Japanese pharma major Shionogi announced the conclusion of a joint research and development agreement and investment ...

French pharma major Sanofi (Euronext: SAN) has received a Complete Response Letter (CRL) from the US regulator for ...

Artificial intelligence remains the most impactful technology shaping the pharmaceutical industry, with companies ...

German biosimilars specialist Formycon (FWB: FYB) has won US approval for Nufymco (ranibizumab), an interchangeable ...

Japan’s Senju Pharmaceutical has announced that Avarept ophthalmic suspension 0.3% (motugivatrep), discovered and licensed by ...

China’s rise as a biopharma innovator is reshaping global drug development, underpinned by regulatory reform and a rapidly ...

US rare disease specialist Agios Pharmaceuticals (Nasdaq: AGIO) has won approval for Aqvesme (mitapivat) to treat anemia in adults with alpha- or beta-thalassaemia, covering both ...

Australian regulator the Therapeutic Goods Administration (TGA) has received an internationally recognized designation from the World Health Organization (WHO), reaffirming TGA’s role as a trusted ...

The US Food and Drug Administration (FDA) has approved Accrufer (ferric maltol) capsules to treat pediatric patients ages 10 and older with iron deficiency.

The year 2025 was a major milestone in the history of rare disease drug development. After decades of slow but steady progress, many long-anticipated drugs were finally approved by regulatory agencies ...